CIBS Network


Innovating Together

In line with our mission to create innovations in brain science of the future for those who need a cure today, we believe that academic researchers must ensure that their discoveries move from the laboratory bench to the patients’ bedside as quickly as possible. Supported by in-house regulatory and intellectual property experts, as well as Tech Launch Arizona, many CIBS investigators have launched companies to further advance the development of their therapeutics.


RASRx, cofounded by Dr's Rodgers and Gaffney, is dedicated to delivering cutting-edge therapeutics for Duchenne Muscular Dystrophy as well as a host of inflammatory and orphan diseases. The RASRx approach is focused on harnessing the body's own regenerative processes.


Regulonix is dedicated to developing novel non-opioid therapeutics for chronic pain. Focusing on non-traditional, sodium channel targets, the team (including Dr. May Khanna) was able to demonstrate their compound to be more effective than morphine, non-addictive, and non-toxic.